Summary:
Segal Trials is currently conducting a study evaluating the safety, effectiveness, and tolerability of two different dosages of the opioid use disorder (OUD) medication, SUBLOCADE® (extended-release buprenorphine). SUBLOCADE is currently approved to suppress withdrawal signs and symptoms in patients who have opioid use disorder.
Taking part in this study will provide information about the best maintenance dosage of SUBLOCADE for those who are seeking treatment for opioid use disorder and have high-risk opioid use.
Qualified Participants Must:
• - Are 18 years of age or older
- Have moderate to severe opioid use disorder and have high-risk opioid use
- Are not currently receiving treatment for opioid use disorder
- Are seeking medical treatment for opioid use
Qualified Participants May Receive:
- All study-related medication
- Study-related medical assessments, monitoring, and counseling by a healthcare professional
- Compensation for qualified participants
- Assistance with travel expenses